Royalty Pharma Plc Cl A (RPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Sales | 575,700 | 585,773 | 554,963 | 573,027 | 572,143 |
| Gross Profit | 575,700 | 585,773 | 554,963 | 573,027 | 572,143 |
| Operating Expenses | 422,283 | 282,721 | -189,986 | 343,730 | 258,087 |
| Operating Income | 153,417 | 303,052 | 744,949 | 229,297 | 314,056 |
| Interest Expense | 46,974 | 44,327 | 37,426 | 37,415 | 37,842 |
| Other Income | -52,772 | -36,929 | 99,232 | -32,903 | 90,414 |
| Pre-tax Income | 53,671 | 221,796 | 806,755 | 158,979 | 366,628 |
| Net Income Continuous | 53,671 | 221,796 | 806,755 | 158,979 | 366,628 |
| Minority Interests | 45,767 | 119,867 | 365,979 | 89,860 | 195,534 |
| Net Income | $7,904 | $101,929 | $440,776 | $69,119 | $171,094 |
| EPS Basic Total Ops | -0.01 | 0.24 | 1.08 | 0.18 | 0.44 |
| EPS Basic Continuous Ops | 0.10 | 0.52 | 1.97 | 0.41 | 1.15 |
| EPS Diluted Total Ops | -0.01 | 0.24 | 1.08 | 0.18 | 0.44 |
| EPS Diluted Continuous Ops | 1.04 | 0.37 | 1.33 | 0.26 | 1.15 |
| EBITDA(a) | $164,553 | $314,087 | $755,475 | $239,758 | $324,698 |